| PCSK9 inhibitor | |
| Usage/dosage | Alirocumab: subcutaneous injection of 75 mg or 150 mg |
| Evolocumab: subcutaneous injection of 140 mg/mL in 2-week interval or 420 mg in 1-month interval | |
| Follow-up test | Lipid profile |
| Adverse reaction | Adverse reactions in the injection site |
| Contraindications | Hypersensitivity to alirocumab or evolocumab |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.